XML 46 R36.htm IDEA: XBRL DOCUMENT
v3.21.2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue recognition (Details) | 3 Months Ended | 6 Months Ended | 12 Months Ended
--- | --- | --- | ---
Jun. 30, 2021 USD ($) | Jun. 30, 2020 USD ($) | Jun. 30, 2021 USD ($) item | Jun. 30, 2020 USD ($) | Dec. 31, 2020 USD ($)
Revenue recognition |  |  |  |  |
Estimated contractual allowance |  |  | $ 3,313,241 |  | $ 3,435,352
Period for return of incorrect shipments |  |  | 10 days |  |
Number of times overstocking returns are limited | item |  |  | 2 |  |
Period for return of product due to overstock |  |  | 12 months |  |
Maximum percentage of distributor's total purchase for the prior 12-month period |  |  | 1.00% |  |
Sales, net | $ 42,496,944 | $ 11,573,845 | $ 92,570,669 | $ 22,776,062 |
Syringes |  |  |  |  |
Revenue recognition |  |  |  |  |
Sales, net | 40,290,601 | 9,269,789 | 87,857,411 | 18,412,338 |
Blood Collection Products |  |  |  |  |
Revenue recognition |  |  |  |  |
Sales, net | 482,108 | 242,870 | 1,093,466 | 827,433 |
Easy Point Needles |  |  |  |  |
Revenue recognition |  |  |  |  |
Sales, net | 1,709,475 | 1,656,712 | 3,478,556 | 2,424,068 |
Other Products |  |  |  |  |
Revenue recognition |  |  |  |  |
Sales, net | 14,760 | 404,474 | 141,236 | 1,112,223 |
Department of health and human |  |  |  |  |
Revenue recognition |  |  |  |  |
Sales, net |  |  | 65,100,000 |  |
U.S. |  |  |  |  |
Revenue recognition |  |  |  |  |
Sales, net | 12,721,896 | 9,409,795 | 23,683,087 | 17,746,592 |
U.S. | Syringes |  |  |  |  |
Revenue recognition |  |  |  |  |
Sales, net | 10,892,733 | 7,492,387 | 19,652,047 | 14,465,322 |
U.S. | Blood Collection Products |  |  |  |  |
Revenue recognition |  |  |  |  |
Sales, net | 456,818 | 235,720 | 1,030,826 | 815,843 |
U.S. | Easy Point Needles |  |  |  |  |
Revenue recognition |  |  |  |  |
Sales, net | 1,358,935 | 1,656,712 | 2,971,268 | 2,422,572 |
U.S. | Other Products |  |  |  |  |
Revenue recognition |  |  |  |  |
Sales, net | 13,410 | 24,976 | 28,946 | 42,855 |
U.S. government |  |  |  |  |
Revenue recognition |  |  |  |  |
Sales, net | 27,357,840 |  | 65,140,200 |  |
U.S. government | Syringes |  |  |  |  |
Revenue recognition |  |  |  |  |
Sales, net | 27,357,840 |  | 65,140,200 |  |
North and South America sales (excluding U.S.) |  |  |  |  |
Revenue recognition |  |  |  |  |
Sales, net | 1,512,388 | 1,943,890 | 2,459,616 | 4,690,290 |
North and South America sales (excluding U.S.) | Syringes |  |  |  |  |
Revenue recognition |  |  |  |  |
Sales, net | 1,467,508 | 1,561,242 | 2,293,328 | 3,616,026 |
North and South America sales (excluding U.S.) | Blood Collection Products |  |  |  |  |
Revenue recognition |  |  |  |  |
Sales, net |  | 5,300 |  | 8,000 |
North and South America sales (excluding U.S.) | Easy Point Needles |  |  |  |  |
Revenue recognition |  |  |  |  |
Sales, net | 44,880 |  | 56,848 | 1,496 |
North and South America sales (excluding U.S.) | Other Products |  |  |  |  |
Revenue recognition |  |  |  |  |
Sales, net |  | 377,348 | 109,440 | 1,064,768 |
Other international sales |  |  |  |  |
Revenue recognition |  |  |  |  |
Sales, net | 904,820 | 220,160 | 1,287,766 | 339,180 |
Other international sales | Syringes |  |  |  |  |
Revenue recognition |  |  |  |  |
Sales, net | 572,520 | 216,160 | 771,836 | 330,990 |
Other international sales | Blood Collection Products |  |  |  |  |
Revenue recognition |  |  |  |  |
Sales, net | 25,290 | 1,850 | 62,640 | 3,590 |
Other international sales | Easy Point Needles |  |  |  |  |
Revenue recognition |  |  |  |  |
Sales, net | 305,660 |  | 450,440 |  |
Other international sales | Other Products |  |  |  |  |
Revenue recognition |  |  |  |  |
Sales, net | $ 1,350 | $ 2,150 | $ 2,850 | $ 4,600 |

X
- Definition For an unclassified balance sheet, a valuation allowance for payables due by the company that are expected to be not payable. + References No definition available. + Details
Name: | rvp_AllowanceForContractualPricing
Namespace Prefix: | rvp_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the maximum percentage of distributor's total purchase in prior 12-month period for overstock return. + References No definition available. + Details
Name: | rvp_RevenueRecognitionMaximumPercentageOfDistributorsTotalPurchaseInPriorTwelveMonthPeriodForOverstockReturn
Namespace Prefix: | rvp_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of overstock returns available to a customer within a specified period of time. + References No definition available. + Details
Name: | rvp_RevenueRecognitionOverstockReturnLimitNumber
Namespace Prefix: | rvp_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The period of time specified for overstock returns. + References No definition available. + Details
Name: | rvp_RevenueRecognitionOverstockReturnPeriod
Namespace Prefix: | rvp_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the period for return of incorrect shipments, following arrival at the distributor's facility. + References No definition available. + Details
Name: | rvp_RevenueRecognitionPeriodForReturnOfIncorrectShipments
Namespace Prefix: | rvp_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=rvp_SyringesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rvp_BloodCollectionProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rvp_EasyPointNeedlesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rvp_OtherProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=rvp_DepartmentOfHealthAndHumanServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=rvp_U.s.GovernmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=rvp_NorthAndSouthAmericaExcludingUnitedStatesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=rvp_OtherInternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |